Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tavapadon + levodopa
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
tavapadon + levodopa is an adjunctive therapeutic regimen combining tavapadon, a once-daily oral selective dopamine D1/D5 receptor partial agonist, with levodopa, a standard dopamine-precursor therapy, for the treatment of Parkinson's disease. Developed by AbbVie (following its acquisition of Cerevel Therapeutics), tavapadon (marketed as Juvmo) was approved by the US FDA in September 2026. The combination is indicated for patients with Parkinson's disease experiencing motor fluctuations. In the Phase 3 TEMPO-3 trial, adding tavapadon to stable levodopa therapy significantly increased daily "ON" time without troublesome dyskinesia and reduced "OFF" time compared to levodopa plus placebo.
- Other names
- Juvmo + levodopaJuvmo plus levodopatavapadon and levodopatavapadon plus levodopa
02
Targets
DDC (Aromatic L-amino acid decarboxylase)DRD1 (Dopamine D1 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on tavapadon + levodopa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tavapadon + levodopa.